# Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

> **NCT06115421** · PHASE4 · UNKNOWN · sponsor: **Alexandria University** · enrollment: 72 (estimated)

## Conditions studied

- Anemia in Dialysis-dependent CKD Patients

## Interventions

- **DRUG:** Roxadustat

## Key facts

- **NCT ID:** NCT06115421
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-24
- **Primary completion:** 2024-03
- **Final completion:** 2024-05
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115421, "Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06115421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*